Kornitzer Capital Management Inc. KS Has $3.79 Million Holdings in Smith & Nephew plc (NYSE:SNN)

Kornitzer Capital Management Inc. KS lowered its stake in Smith & Nephew plc (NYSE:SNN - Free Report) by 49.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 154,254 shares of the medical equipment provider's stock after selling 151,355 shares during the quarter. Kornitzer Capital Management Inc. KS's holdings in Smith & Nephew were worth $3,792,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of SNN. Creative Planning lifted its stake in Smith & Nephew by 28.6% in the third quarter. Creative Planning now owns 62,319 shares of the medical equipment provider's stock valued at $1,941,000 after buying an additional 13,845 shares in the last quarter. Blue Trust Inc. lifted its position in shares of Smith & Nephew by 460.5% in the third quarter. Blue Trust Inc. now owns 4,658 shares of the medical equipment provider's stock worth $145,000 after purchasing an additional 3,827 shares in the last quarter. Raymond James & Associates lifted its position in shares of Smith & Nephew by 172.1% in the third quarter. Raymond James & Associates now owns 128,854 shares of the medical equipment provider's stock worth $4,013,000 after purchasing an additional 81,500 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its position in shares of Smith & Nephew by 74.4% in the third quarter. Allspring Global Investments Holdings LLC now owns 3,025 shares of the medical equipment provider's stock worth $94,000 after purchasing an additional 1,290 shares in the last quarter. Finally, Signaturefd LLC lifted its position in shares of Smith & Nephew by 18.7% in the third quarter. Signaturefd LLC now owns 15,119 shares of the medical equipment provider's stock worth $471,000 after purchasing an additional 2,384 shares in the last quarter. Institutional investors own 25.64% of the company's stock.

Wall Street Analyst Weigh In

SNN has been the topic of a number of research reports. StockNews.com lowered shares of Smith & Nephew from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, November 12th. Berenberg Bank lowered shares of Smith & Nephew from a "buy" rating to a "hold" rating in a research report on Wednesday, November 6th. Finally, Deutsche Bank Aktiengesellschaft lowered shares of Smith & Nephew from a "buy" rating to a "hold" rating in a research report on Friday, November 1st.

Smith & Nephew Trading Up 1.6 %

NYSE SNN traded up $0.41 on Friday, hitting $26.13. 509,385 shares of the stock were exchanged, compared to its average volume of 759,688. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.11 and a current ratio of 2.51. The business's fifty day moving average is $25.03 and its 200 day moving average is $27.32. Smith & Nephew plc has a 52 week low of $23.65 and a 52 week high of $31.72.

Smith & Nephew Company Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.